Sensus Healthcare SRT-100 Cure Rate Exceeds 97%, Study Suggests

The cure rate from use of Sensus Healthcare's SRT-100 for treating basal and squamous cell carcinomas of the lower extremities among older patients (mean age: 82.5 years) exceeds 97%, according to a retrospective study published in the Journal of Drugs in Dermatology.